A probiotic product for relieving diabetes and prediabetes, preparation method and application thereof

Abstract

The present invention relates to a probiotic product for relieving diabetes and prediabetes, a preparation method and application thereof, comprising Lactobacillus plantarum AR113; or Lactobacillus plantarum AR113 and mulberry leaf extract. The probiotic product has the advantages that under the action of Lactobacillus plantarum AR113 or the synergistic action of Lactobacillus plantarum AR113 and mulberry leaf extract, diabetes can be better alleviated, and Lactobacillus plantarum AR113 also has a good effect on prediabetes by repairing pancreatic damage, reducing oxidative damage and liver glycolysis function, and can prevent and treat diabetes or prediabetes.

Description

Technical Field

[0001] The present invention relates to the technical field of biological products, and in particular to a probiotic product for alleviating diabetes and prediabetes, a preparation method and application thereof. Background Art

[0002] There are currently two methods for treating diabetes: one is insulin injection, but it may cause insulin resistance; the second is oral hypoglycemic drugs, but long-term use of drugs can cause some side effects and affect the patient's health.

[0003] Prediabetes refers to a state in which blood sugar is higher than normal but not yet diagnosed as diabetes, which is the intermediate group between normal people and diabetic patients.

[0004] The current treatment of diabetes is mainly aimed at inhibiting the activity of α-glucosidase. α-glucosidase can release glucose by hydrolyzing glucosidic bonds, leading to increased blood sugar in the body. It is an important substance involved in sugar metabolism in the body. Inhibiting α-glucosidic bonds is a treatment angle for alleviating diabetes. By inhibiting this type of enzyme, the absorption of carbohydrates can be delayed. It is mainly used to reduce postprandial hyperglycemia and is suitable for patients with hyperglycemia whose main diet is carbohydrates. However, the scope of application of relieving diabetes by inhibiting α-glucosidase is limited, and it has little effect on diabetic patients with other non-carbohydrate diets. And for patients who have already developed hyperglycemia, it is difficult to regulate other metabolic pathways in the body to achieve fundamental relief.

[0005] Therefore, it is necessary to develop biological products containing live probiotics with higher health value to open up new pathways and solutions for alleviating diabetes using dietary strategies.

[0006] In order to prevent and treat diabetes or prediabetes and alleviate the technical problems of damage to the body caused by diabetes, a probiotic product, preparation method and application for relieving diabetes and prediabetes are proposed based on dietary strategies for relieving diabetes. Summary of the invention

[0007] The purpose of the present invention is to provide a probiotic product, preparation method and application for relieving diabetes and prediabetes in view of the deficiencies in the prior art, so as to prevent and treat diabetes or prediabetes and relieve the damage caused to the body by diabetes; the probiotic AR113 with blood sugar regulating effect of the present invention is used alone or in combination with mulberry leaf extract, which can fundamentally relieve the damage caused to the body by diabetes, and to a certain extent enriches the research on the effect of probiotics on relieving diabetes; the present invention makes a certain contribution to the prevention and treatment of diabetes or prediabetes by probiotics or probiotic mulberry leaf extract compounds, and provides various forms of biological preparations.

[0008] To achieve the above object, the technical solution adopted by the present invention is:

[0009] In a first aspect, the present invention provides a probiotic preparation for alleviating diabetes and prediabetes, comprising:

[0010] Lactobacillus plantarum AR113;

[0011] Wherein, the viable count of the Lactobacillus plantarum AR113 is not less than 10^6 CFU / ml or 10^6 CFU / g, and the Lactobacillus plantarum AR113 strain has been deposited in the General Microbiological Center of China National Committee for Microbiological Culture Collection on March 22, 2017, with the address of No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 13909; or

[0012] Lactobacillus plantarum AR113 and mulberry leaf extract;

[0013] Among them, the viable bacterial count of the Lactobacillus plantarum AR113 is not less than 10^6 CFU / ml or 10^6 CFU / g, the Lactobacillus plantarum AR113 strain has been deposited in the General Microbiology Center of the China Microorganism Culture Collection Administration on March 22, 2017, with a deposit number of CGMCC No.13909; the ratio of the content of the mulberry leaf extract to the content of the Lactobacillus plantarum AR113 is 10% to 60%.

[0014] In some of the embodiments, the finished product state of the biological product includes powder, granular, and liquid.

[0015] In a second aspect, the present invention provides a method for preparing a probiotic product for alleviating diabetes and prediabetes, which is used to prepare the probiotic product as described in the first aspect, comprising:

[0016] Lactobacillus plantarum AR113 is prepared into probiotic products of different dosage forms;

[0017] Wherein, in the probiotic product, the viable count of Lactobacillus plantarum AR113 is not less than 10^6CFU / ml or 10^6CFU / g; or

[0018] The Lactobacillus plantarum AR113 and mulberry leaf extract are compounded to obtain a probiotic product;

[0019] Among them, in the probiotic product, the viable bacterial count of the Lactobacillus plantarum AR113 is not less than 10^6 CFU / ml or 10^6 CFU / g, and the ratio of the content of the mulberry leaf extract to the content of the Lactobacillus plantarum AR113 is 10% to 60%.

[0020] In some of the embodiments, including:

[0021] Lactobacillus plantarum AR113 is made into powder / tablet / solution.

[0022] In some embodiments, the Lactobacillus plantarum AR113 is freeze-dried, spray-dried, or spray-freeze-dried to prepare a powder / tablet.

[0023] In some of the embodiments, including:

[0024] Lactobacillus plantarum AR113 and mulberry leaf extract are compounded to prepare powder / tablets / solution.

[0025] In some embodiments, the powdered Lactobacillus plantarum AR113 and the powdered mulberry leaf extract are compounded to prepare powders / tablets.

[0026] In some embodiments, the powdered Lactobacillus plantarum AR113 is added to the liquid mulberry leaf extract to prepare a solution.

[0027] In some of the embodiments, including:

[0028] Lactobacillus plantarum AR113 is added to the crude filtrate of mulberry leaf extract for cultivation to obtain a fermentation broth containing live AR113 bacteria, wherein the number of live bacteria of Lactobacillus plantarum AR113 in the fermentation broth is not less than 10^6 CFU / ml, and the ratio of the content of the mulberry leaf extract to the content of the Lactobacillus plantarum AR113 is 10% to 60%.

[0029] In some embodiments, the method for preparing the crude filtrate of the mulberry leaf extract comprises:

[0030] Cut the mulberry leaves into shreds to obtain mulberry leaf shreds;

[0031] Add mulberry leaf shreds into water and steam at high temperature for 1 hour to obtain mulberry leaf steaming liquid, wherein the volume ratio of mulberry leaf shreds to water is 1:5-10;

[0032] The mulberry leaf cooking liquid is filtered to obtain a coarse filtrate of mulberry leaf extract.

[0033] In some of the embodiments, including:

[0034] Lactobacillus plantarum AR113 is added to the refined filtrate of mulberry leaf extract to obtain a bacterial suspension containing Lactobacillus plantarum AR113, wherein in the bacterial suspension, the number of viable bacteria of Lactobacillus plantarum AR113 is not less than 10^6 CFU / ml, and the ratio of the content of the mulberry leaf extract to the content of the Lactobacillus plantarum AR113 is 10% to 60%.

[0035] In some embodiments, the method for preparing the refined filtrate of the mulberry leaf extract comprises:

[0036] Cut the mulberry leaves into shreds to obtain mulberry leaf shreds;

[0037] Add mulberry leaf shreds into water and steam at high temperature for 1 hour to obtain mulberry leaf steaming liquid, wherein the volume ratio of mulberry leaf shreds to water is 1:5-10;

[0038] filtering the mulberry leaf cooking liquid to obtain a coarse filtrate of mulberry leaf extract;

[0039] The coarse filtrate of the mulberry leaf extract is filtered through a 0.45 μm filter membrane to obtain a fine filtrate of the mulberry leaf extract.

[0040] In some of the embodiments, it also includes:

[0041] The bacterial suspension is freeze-dried to obtain a probiotic compound powder.

[0042] In a third aspect, the present invention provides a use of the probiotic preparation as described in the first aspect in the preparation of health products, foods, and medicines for alleviating diabetes and prediabetes.

[0043] In some of the embodiments, in the health product, the food or the medicine, the viable count of the Lactobacillus plantarum AR113 is not less than 10^6 CFU / ml or 10^6 CFU / g.

[0044] In some of the embodiments, in the health product, the food or the medicine, the ratio of the content of the mulberry leaf extract to the content of the Lactobacillus plantarum AR113 is 10% to 60%.

[0045] The present invention adopts the above technical solution, and has the following technical effects compared with the prior art:

[0046] The invention discloses a probiotic product for relieving diabetes and prediabetes, a preparation method and an application thereof. Through the action of Lactobacillus plantarum AR113 or the synergistic action of Lactobacillus plantarum AR113 and mulberry leaf extract, diabetes can be better relieved. Lactobacillus plantarum AR113 also has a good effect on prediabetes by repairing pancreatic damage, reducing oxidative damage and liver glycolysis function, and can prevent and treat diabetes or prediabetes. After Lactobacillus plantarum AR113 is compounded with mulberry leaf extract, the inhibition of alpha-glucosidase activity and insulin secretion are effectively improved, and the blood sugar lowering effect and the effect of relieving prediabetes are good. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1is a diagram of a design scheme for an animal experiment on type 2 diabetes according to an embodiment of the present invention;

[0048] Figure 2a This is an expression diagram of the pancreatic β cells of group N according to an embodiment of the present invention, in which the pancreatic β cells are stained brown as positive cells by specific antibodies;

[0049] Figure 2b This is an expression diagram of pancreatic β cells in the DM group according to an embodiment of the present invention, which are stained brown as positive cells by specific antibodies;

[0050] Figure 2c This is an expression diagram of pancreatic β cells in the DM-AR113 group according to an embodiment of the present invention, in which the pancreatic β cells are stained brown as positive cells by specific antibodies;

[0051] Figure 2d This is an expression diagram of pancreatic β cells in the DM-AR495 group according to an embodiment of the present invention, in which the pancreatic β cells are stained brown as positive cells by specific antibodies;

[0052] Figure 2e is a unit islet expression intensity map according to an embodiment of the present invention;

[0053] Figure 3 is a graph showing insulin content in rats of each group after the experiment according to an embodiment of the present invention;

[0054] Figure 4a CAT index diagram of each model rat according to an embodiment of the present invention;

[0055] Figure 4b : is a graph of SOD indexes of various model rats according to an embodiment of the present invention;

[0056] Figure 4c is a graph showing the GSH-PX index of each model rat according to an embodiment of the present invention;

[0057] Figure 4d is an MDA index diagram of each model rat according to an embodiment of the present invention;

[0058] Figure 5 1 is an expression diagram of key glycolytic enzymes in each model rat according to the embodiments of the present invention. DETAILED DESCRIPTION

[0059] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0060] It should be noted that, in the absence of conflict, the embodiments of the present invention and the features in the embodiments may be combined with each other.

[0061] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments, but they are not intended to limit the present invention.

[0062] Example 1

[0063] This embodiment relates to the probiotic preparation and application of the present invention.

[0064] A probiotic product for relieving diabetes and prediabetes, comprising Lactobacillus plantarum AR113;

[0065] Among them, the viable count of Lactobacillus plantarum AR113 is not less than 10^6 CFU / ml or 10^6 CFU / g. The Lactobacillus plantarum AR113 strain has been deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration on March 22, 2017, with the deposit number CGMCC No.13909.

[0066] The finished product state of the probiotic product includes powder, granule and liquid.

[0067] In some embodiments, the viable count of Lactobacillus plantarum AR113 is no higher than 10^12 CFU / ml or 10^12 CFU / g.

[0068] A use of the probiotic product as described above in the preparation of health products, foods and medicines for relieving diabetes and prediabetes.

[0069] In health products, foods or medicines, the viable count of Lactobacillus plantarum AR113 is not less than 10^6 CFU / ml or 10^6 CFU / g.

[0070] The advantage of this embodiment is that under the action of Lactobacillus plantarum AR113, diabetes can be better alleviated. Lactobacillus plantarum AR113 also has a good effect on prediabetes by repairing pancreatic damage, reducing oxidative damage and liver glycolysis function, and can prevent and treat diabetes or prediabetes.

[0071] Example 2

[0072] This embodiment relates to the preparation method of the present invention.

[0073] A method for preparing a probiotic product for relieving diabetes and prediabetes, which is used to prepare the probiotic product as described in Example 1, comprising preparing Lactobacillus plantarum AR113 alone into probiotic products of different dosage forms.

[0074] Furthermore, Lactobacillus plantarum AR113 is prepared into powder / tablet / solution.

[0075] In some embodiments, the preparation method comprises:

[0076] Lactobacillus plantarum AR113 was freeze-dried, spray-dried, or spray-freeze-dried to prepare powders / tablets.

[0077] In some embodiments, the preparation method comprises:

[0078] Lactobacillus plantarum AR113 was added to the milk product to prepare a solution.

[0079] Furthermore, the solution includes but is not limited to yogurt and milk drinks.

[0080] Example 3

[0081] This embodiment relates to the probiotic preparation and application of the present invention.

[0082] A probiotic product for relieving diabetes and prediabetes, comprising Lactobacillus plantarum AR113 and mulberry leaf extract;

[0083] Among them, the viable bacterial count of Lactobacillus plantarum AR113 is not less than 10^6 CFU / ml or 10^6 CFU / g. The Lactobacillus plantarum AR113 strain has been deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on March 22, 2017, with the deposit number CGMCC No.13909; the ratio of the content of mulberry leaf extract to the content of Lactobacillus plantarum AR113 is 10% to 60%.

[0084] The finished product state of the probiotic product includes powder, granule and liquid.

[0085] In some embodiments, the viable count of Lactobacillus plantarum AR113 is no higher than 10^12 CFU / ml or 10^12 CFU / g.

[0086] A use of the probiotic product as described above in the preparation of health products, foods and medicines for relieving diabetes and prediabetes.

[0087] In the health care product, food or medicine, the viable bacterial count of Lactobacillus plantarum AR113 is not less than 10^6 CFU / ml or 10^6 CFU / g, and the ratio of the content of mulberry leaf extract to the content of Lactobacillus plantarum AR113 is 10% to 60%.

[0088] The advantage of this embodiment is that under the synergistic effect of Lactobacillus plantarum AR113 and mulberry leaf extract, diabetes can be better alleviated. Lactobacillus plantarum AR113 also has a good effect on prediabetes by repairing pancreatic damage, reducing oxidative damage and liver glycolysis function, and can prevent and treat diabetes or prediabetes.

[0089] Example 4

[0090] This embodiment relates to the preparation method of the present invention.

[0091] A method for preparing a probiotic product for relieving diabetes and prediabetes, which is used to prepare the probiotic product as described in Example 1, comprising:

[0092] The Lactobacillus plantarum AR113 and mulberry leaf extract are compounded to obtain a probiotic product;

[0093] Among them, in the probiotic product, the number of live bacteria of Lactobacillus plantarum AR113 is not less than 10^6 CFU / ml or 10^6 CFU / g, and the ratio of the content of mulberry leaf extract to the content of Lactobacillus plantarum AR113 is 10% to 60%.

[0094] Example 5

[0095] This embodiment is a specific embodiment of Embodiment 4.

[0096] A method for preparing a probiotic product for relieving diabetes and prediabetes, comprising:

[0097] freeze-drying or spray-freeze-drying the Lactobacillus plantarum AR113 and the solution containing the mulberry leaf extract, respectively, to obtain Lactobacillus plantarum AR113 powder and mulberry leaf extract powder;

[0098] The Lactobacillus plantarum AR113 powder and the mulberry leaf extract powder are compounded to obtain the probiotic compound powder.

[0099] Example 6

[0100] This embodiment is a specific embodiment of Embodiment 4.

[0101] A method for preparing a probiotic product for relieving diabetes and prediabetes, comprising:

[0102] Compounding powdered Lactobacillus plantarum AR113 and powdered mulberry leaf extract to obtain a probiotic compound powder; or

[0103] The powdered Lactobacillus plantarum is added to the liquid mulberry leaf extract to prepare a solution.

[0104] Example 7

[0105] This embodiment is a specific embodiment of Embodiment 4.

[0106] A method for preparing a probiotic product for relieving diabetes and prediabetes comprises adding Lactobacillus plantarum AR113 to a crude filtrate of a mulberry leaf extract for culturing to obtain a fermentation broth containing live AR113 bacteria, wherein the number of live bacteria of Lactobacillus plantarum AR113 in the fermentation broth is not less than 10^6 CFU / ml, and the ratio of the content of the mulberry leaf extract to the content of Lactobacillus plantarum AR113 is 10% to 60%.

[0107] Wherein, the preparation method of the crude filtrate of mulberry leaf extract comprises:

[0108] Cut the mulberry leaves into shreds to obtain mulberry leaf shreds;

[0109] Add mulberry leaf shreds into water and steam at high temperature for 1 hour to obtain mulberry leaf steaming liquid, wherein the volume ratio of mulberry leaf shreds to water is 1:5-10;

[0110] The mulberry leaf cooking liquid is filtered to obtain a coarse filtrate of the mulberry leaf extract.

[0111] Example 8

[0112] This embodiment is a specific embodiment of Embodiment 4.

[0113] A method for preparing a probiotic product for relieving diabetes and prediabetes comprises adding Lactobacillus plantarum AR113 to a refined filtrate of a mulberry leaf extract to obtain a bacterial suspension containing Lactobacillus plantarum AR113, wherein in the bacterial suspension, the number of viable bacteria of Lactobacillus plantarum AR113 is not less than 10^6 CFU / ml, and the ratio of the content of the mulberry leaf extract to the content of Lactobacillus plantarum AR113 is 10% to 60%.

[0114] The preparation method of the refined filtrate of mulberry leaf extract comprises:

[0115] Cut the mulberry leaves into shreds to obtain mulberry leaf shreds;

[0116] Add mulberry leaf shreds into water and steam at high temperature for 1 hour to obtain mulberry leaf steaming liquid, wherein the volume ratio of mulberry leaf shreds to water is 1:5-10;

[0117] Filtering the mulberry leaf cooking liquid to obtain a crude filtrate of the mulberry leaf extract;

[0118] The crude filtrate of the mulberry leaf extract was filtered through a 0.45 μm filter membrane to obtain the refined filtrate of the mulberry leaf extract.

[0119] In some of the embodiments, the viable count of Lactobacillus plantarum AR113 is 10^6 to 10^11 CFU / ml.

[0120] Example 9

[0121] This embodiment is a variation of Embodiment 8.

[0122] A method for preparing a probiotic product for alleviating diabetes and prediabetes comprises freeze-drying the bacterial suspension of Example 6 to obtain a probiotic compound powder.

[0123] Mulberry leaf extract can be used as a good cryoprotectant. Specifically, Lactobacillus plantarum AR113 was freeze-dried alone, Lactobacillus plantarum AR113 was freeze-dried with sorbitol, Lactobacillus plantarum AR113 was freeze-dried with buffer PBS, and Lactobacillus plantarum AR113 and mulberry leaf extract were freeze-dried. Among them, the survival rate of the strain without adding a protective agent was the lowest, the survival rate of the strain with buffer PBS was second, the survival rate of the strain with a protective agent was higher, and the survival rate of the strain with mulberry leaf extract was the highest. Compared with buffer solution PBS, the strain survival rate increased by 220%; compared with the commonly used freeze-drying protective agent sorbitol, the strain survival rate increased by 90%. In the absence of a protective agent, when mulberry leaf extract was present, the strain survival rate was at least 85%.

[0124] Example 10

[0125] This example is a test of the probiotic preparation of the present invention on alleviating diabetes.

[0126] Effects of probiotic intervention on pancreatic function in rats

[0127] (I) Establishment of type 2 diabetes rat model and probiotic intervention experiment

[0128] like Figure 1 As shown, 7-week-old male SD rats were used in the experiment. In the first week, they were adaptively fed with normal diet.

[0129] In the second week, the mice were randomly divided into a high-fat diet group and a basic diet group according to their body weight and fed for 6 weeks. The high-fat diet contained 20% protein, 20% carbohydrates and 60% fat, with an energy of 5242 kcal / kg.

[0130] After the high-fat feeding, the rats were modeled: all rats were fasted (but not water) for 16 hours, and then the rats were weighed and recorded, and the amount of STZ injection was calculated based on the body weight. Rats in the high-fat diet group were intraperitoneally injected with STZ (25 mg / kg·BW), and the injection volume was 0.5 mL / 100 g·BW. STZ was dissolved in 50 mmol / L, pH 4.5 sodium citrate buffer. Since STZ was unstable, it needed to be placed in an ice bath away from light and prepared and used within 30 minutes. Rats in the basal diet group were injected with citric acid-sodium citrate buffer. After the injection, all rats were fed with basal feed.

[0131] AR113 and AR495 were used for intervention experiments.

[0132] (II) Immunohistochemical analysis of pancreatic β cells

[0133] like Figure 2a Figures 4 and 5 show the expression of pancreatic β cells in each group of models, which were stained brown by specific antibodies as positive cells, and the remaining cells were exocrine gland cells.

[0134] Observation and analysis showed that the pancreatic β cells of rats in group N were intact, with regular shapes and clear edges. The cells were round or oval, and the islet morphology was normal. The number of pancreatic β cells in group DM was scarce and the pancreatic β cells were severely damaged, which was due to the destruction of pancreatic β cells by injection of STZ. In group DM-AR113, although the pancreatic β cells were damaged, the number of pancreatic β cells increased significantly compared with that in group DM. In group DN-AR495, the pancreatic β cells were severely damaged and the number of pancreatic β cells was very scarce.

[0135] from Figure 2e It can be seen that the positive expression intensity of islets per unit area in the DM group was significantly lower than that in the N group, while treatment with Lactobacillus plantarum AR113 significantly increased the expression of islet intensity. The above results show that Lactobacillus plantarum AR113 can increase the number of pancreatic β cells and has a good repair effect on pancreatic β cells.

[0136] (III) Insulin experimental content analysis

[0137] like Figure 3 As shown, compared with the N group, the insulin content in the DM group rats was significantly reduced, indicating that the pancreatic β cells of the diabetic rats were severely damaged and the pancreatic β cells failed, resulting in reduced insulin secretion; after intervention with Lactobacillus plantarum AR113, the insulin content in the rats increased significantly compared with the DM group, increasing by about 2.8 times.

[0138] By measuring blood sugar, it was found that the blood sugar of rats in the DM-AR113 group gradually decreased over time. At the same time, compared with the DM group, after intragastric administration of Lactobacillus plantarum AR113, the blood sugar of rats decreased significantly in the third week (P<0.01). Therefore, continuous intragastric administration of Lactobacillus plantarum AR113 can significantly improve the blood sugar of rats with type 2 diabetes.

[0139] Oxidative stress index

[0140] Catalase (CAT) Figure 4a As shown; superoxide dismutase (SOD) as Figure 4b As shown; glutathione peroxidase (GSH-PX) as Figure 4c As shown; malondialdehyde (MDA) as Figure 4d shown.

[0141] Through 8 weeks of oral administration of AR113, it can be seen that compared with the DM group, AR113 can significantly increase the activity of CAT and regulate the activities of SOD and GSH-Px to a certain extent; while the activities of CAT, SOD, and GSH-Px in the liver of rats in the AR495 group were not significantly different from those in the DM group. This indicates that Lactobacillus plantarum AR113 can increase the antioxidant activity in rats with type 2 diabetes and reduce oxidative damage in rats with type 2 diabetes to a certain extent.

[0142] Key enzymes of glycolysis

[0143] Glycolysis involves three key rate-limiting enzymes: hexokinase (GK), 6-phosphofructokinase and pyruvate kinase. GK is the first rate-limiting enzyme in the glycolysis pathway and is also one of the key enzymes regulating sugar metabolism and insulin secretion.

[0144] like Figure 5 As shown in the figure, the relative expression of GK in the DM group was significantly reduced (P<0.05), indicating that the process of glucose conversion to pyruvate was inhibited, which hindered the utilization of glucose in the liver and led to the increase of blood glucose in diabetic rats.

[0145] Compared with the DM group, the relative expression of GK in rats treated with Lactobacillus plantarum AR113 was significantly increased, which can effectively promote the liver's utilization of glucose.

[0146] The above results show that the glycolysis process of diabetic rats is inhibited, and Lactobacillus plantarum AR113 can promote the expression of GK, a key rate-limiting enzyme in the glycolysis process, and has a certain effect on maintaining relative stability of blood sugar. AR113 can regulate the increase in the expression of GK, a key rate-limiting enzyme in the glycolysis process of the body, and can be used to lose weight for obese people or regulate the weight of obese diabetic patients.

[0147] Embodiment 11

[0148] This example is a test of the probiotic preparation of the present invention on alleviating diabetes.

[0149] In this embodiment, an experimental group and a control group are set to conduct the experiment, as follows:

[0150]

[0151]

[0152] Experiments have shown that, within the range of 0-10%, the effect of increasing the content of mulberry leaf extract on blood sugar is weaker; within the range of 10%-60%, as the content of mulberry leaf extract increases, the blood sugar lowering effect gradually increases; when the content of mulberry leaf extract exceeds 60%, the blood sugar lowering effect weakens.

[0153] Compared with Lactobacillus plantarum AR113 or mulberry leaf extract alone, the effect of the combination of Lactobacillus plantarum AR113 and mulberry leaf extract is significantly better than that of Lactobacillus plantarum AR113 or mulberry leaf extract. The blood sugar lowering effect after the combination is improved by at least 10%, the inhibition of α-glucosidase activity after the combination is improved by 53% compared with AR113 alone, and the insulin secretion after the combination is increased by 62% compared with mulberry leaf extract alone, and 47% compared with AR113. Through the combination, the blood sugar lowering effect or relief of prediabetes is better than that of Lactobacillus plantarum AR113 or mulberry leaf extract alone, and has a significant synergistic effect.

[0154] Effects of mulberry leaf extract

[0155] The hypoglycemic effect of mulberry leaves is achieved through two pathways: first, the alkaloid DNJ (1-deoxynojirimycin) inhibits the activity of disaccharide degrading enzymes, thereby inhibiting the absorption of disaccharides in the small intestine and reducing the peak value of blood sugar after a meal; second, mulberry leaf alkaloids (fagomine) and mulberry leaf polysaccharides promote the secretion of insulin by β cells, and insulin can promote the cell's utilization of sugar, liver glycogen synthesis, and improve sugar metabolism, ultimately achieving the effect of lowering blood sugar.

[0156] The above description is only a preferred embodiment of the present invention, and does not limit the implementation mode and protection scope of the present invention. For those skilled in the art, it should be aware that all solutions obtained by equivalent substitutions and obvious changes made using the description and illustrations of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing a probiotic product for relieving diabetes and prediabetes, characterized in that: include: Lactobacillus plantarum ( lactobacillus plantarum ) AR113 is added to the refined filtrate of mulberry leaf extract to obtain a bacterial suspension containing Lactobacillus plantarum AR113, wherein in the bacterial suspension, the viable count of Lactobacillus plantarum AR113 is not less than 10^6 CFU / ml, and the ratio of the content of the mulberry leaf extract to the content of the Lactobacillus plantarum AR113 is 10%~60%; freeze-drying the bacterial suspension to obtain a probiotic compound powder; Wherein, the preparation method of the refined filtrate of the mulberry leaf extract comprises: Cut the mulberry leaves into shreds to obtain mulberry leaf shreds; Add mulberry leaf shreds into water and cook at high temperature for 1 hour to obtain mulberry leaf cooking liquid, wherein the volume ratio of mulberry leaf shreds to water is 1:5-10; filtering the mulberry leaf cooking liquid to obtain a coarse filtrate of mulberry leaf extract; Filtering the crude filtrate of the mulberry leaf extract through a 0.45 μm filter membrane to obtain a refined filtrate of the mulberry leaf extract; Among them, the viable bacterial count of the plant lactobacillus AR113 is not less than 10^6CFU / ml or 10^6CFU / g, and the plant lactobacillus AR113 strain has been deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on March 22, 2017, with a deposit number of CGMCC No. 13909.

Images